Eton Net Interest Income from 2010 to 2026
| ETON Stock | USD 17.15 0.08 0.47% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter -1 M | Current Value -592 K | Quarterly Volatility 385.8 K |
Check Eton Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eton Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 750.3 K or Interest Expense of 2.4 M, as well as many indicators such as Price To Sales Ratio of 9.66, Dividend Yield of 0.0214 or PTB Ratio of 6.65. Eton financial statements analysis is a perfect complement when working with Eton Pharmaceuticals Valuation or Volatility modules.
Eton | Net Interest Income | Build AI portfolio with Eton Stock |
Evaluating Eton Pharmaceuticals's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Eton Pharmaceuticals's fundamental strength.
Latest Eton Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Eton Pharmaceuticals over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Eton Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eton Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Eton Net Interest Income Regression Statistics
| Arithmetic Mean | (217,783) | |
| Geometric Mean | 340,108 | |
| Coefficient Of Variation | (277.01) | |
| Mean Deviation | 547,719 | |
| Median | 164,000 | |
| Standard Deviation | 603,285 | |
| Sample Variance | 364B | |
| Range | 1.7M | |
| R-Value | (0.70) | |
| Mean Square Error | 198.6B | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | (83,496) | |
| Total Sum of Squares | 5.8T |
Eton Net Interest Income History
About Eton Pharmaceuticals Financial Statements
Eton Pharmaceuticals investors utilize fundamental indicators, such as Net Interest Income, to predict how Eton Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -1.1 M | -1 M |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.67 | SFZN | Siegfried Holding Earnings Call This Week | PairCorr |
| 0.63 | DYF1 | Dynavax Technologies Earnings Call Tomorrow | PairCorr |
| 0.61 | VTYX | Ventyx Biosciences | PairCorr |
| 0.61 | ELVN | Enliven Therapeutics | PairCorr |
| 0.6 | ELAN | Elanco Animal Health Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eton Pharmaceuticals Correlation against competitors. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Pharmaceuticals sector continue expanding? Could Eton diversify its offerings? Factors like these will boost the valuation of Eton Pharmaceuticals. Projected growth potential of Eton fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eton Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 1.175 | Return On Assets |
Investors evaluate Eton Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Eton Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Eton Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Eton Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eton Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Eton Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.